Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. ‘I actually started crying’
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
Original Source
Read the full article at Fortune →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.